



Rockwell Medical Schedules Second Quarter 2018 Business Update Conference Call and Provides Timeline of Form 10-Q Filing

August 3, 2018

WIXOM, Mich., Aug. 3, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company") announced today that it will hold a conference call to provide commentary on the business on Tuesday, August 14, 2018, at 5:00 pm Eastern Time. A copy of the earnings release for the second quarter 2018 will be made available on August 14, 2018 after the markets close.

This second quarter 2018 business update conference call is also being webcast and can be accessed at the Rockwell Medical Investor Relations web page. You can join this call on:

Date: Tuesday, August 14
Time: 5:00 pm ET
Dial in number: (866) 610-1072
International dial in: (973) 935-2840
Passcode: 3884015
Webcast: <http://ir.rockwellmed.com>

The Company also announced that on or before August 9, 2018, Rockwell Medical intends to file a Form 12b-25 with the Securities and Exchange Commission providing the Company an automatic 5-day extension to file its Form 10-Q for the quarter ended June 30, 2018. As previously disclosed, the Company engaged Marcum LLP as the Company's new independent registered public accounting firm on July 26, 2018. The Company is working diligently and plans to use the extension to complete its work and file its second quarter Form 10-Q within the 5-day extension period provided by Rule 12b-25.

About Rockwell Medical, Inc.

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and other major markets globally.

Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to bring to market Triferic and Calcitriol. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including without limitation those set forth in Rockwell's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the ongoing litigation with Rockwell's former Chief Executive Officer, Chief Financial Officer and certain current and former directors; the timing for the appointment of a successor Chief Executive Officer, Chief Financial Officer; Rockwell's ability to maintain compliance with SEC and NASDAQ rules and requests; and whether Rockwell can successfully execute on its business strategy. Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Dan Katcher / Kelly Sullivan / Arielle Rothstein
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

 View original content: <http://www.prnewswire.com/news-releases/rockwell-medical-schedules-second-quarter-2018-business-update-conference-call-and-provides-timeline-of-form-10-q-filing-300691695.html>

SOURCE Rockwell Medical, Inc.